Congress Asset Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Congress Asset Management’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-492,556	Closed	-$1.15M	–	388
2022 Q3	$1.15M	Sell	492,556 -48,571	-9%	-$172K	0.01%	298
2022 Q2	$1.64M	Buy	541,127 +11,304	+2%	+$55K	0.02%	292
2022 Q1	$3.6M	Buy	529,823 +148,777	+39%	+$1.06M	0.03%	253
2021 Q4	$3.18M	Buy	381,046 +112	+0%	+$923	0.02%	253
2021 Q3	$2.83M	Buy	380,934 +22,535	+6%	+$140K	0.02%	250
2021 Q2	$2.44M	Buy	358,399 +255,629	+249%	+$2.12M	0.02%	259
2021 Q1	$1.05M	Buy	102,770 +10,420	+11%	+$114K	0.01%	294
2020 Q4	$646K	Sell	92,350 -1,280	-1%	-$9.96K	0.01%	299
2020 Q3	$764K	Hold	93,630	–	–	0.01%	273
2020 Q2	$646K	Buy	93,630 +1,160	+1%	+$6.26K	0.01%	276
2020 Q1	$439K	Buy	+92,470	New	+$532K	0.01%	290

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Congress Asset Management's JNCE Position: Q4 2022 in Review

Congress Asset Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 492,556 shares — an estimated $1.15M sold.

Congress Asset Management first reported a position in JNCE in Q1 2020 and held it in 11 quarters. The position peaked at $3.6M in Q1 2022. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

Congress Asset Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Congress Asset Management sold 492,556 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1.15M.
Congress Asset Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
Congress Asset Management's Jounce Therapeutics, Inc. Common Stock position peaked at $3.6M in Q1 2022.
85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Congress Asset Management's 13F filing for Q4 2022, filed 18 Jan 2023.